Background: HCV infection in children differs from infection in adult through transmission paths,
INTRODUCTION
The hepatitis C virus (HCV) was identified in 1989 (1) , and to date is one of the most important cause of chronic liver disease worldwide (2) , which affects 2% of the adult population with some regional variations. The number of children affected is estimated at between 23,000 and 46,000 in the United States of America and 6,600 children in Canada (3, 4) . From 1998 to 2009, 133 liver transplants were performed due to secondary liver failure as consequence of chronic hepatitis C virus infection and have been reported only two cases of hepatocellular carcinoma; however the existence of more cases cannot be ignored (5) .
In the adults, HCV infection aggravates in an acute phase which is asymptomatic, and a large proportion progresses to chronic, cirrhosis and hepatocellular carcinoma (6, 7) leading to 600,000 deaths every year (8) . Only a small proportion of the population with chronic hepatitis C is observed in children (9, 10) . There are reports of hepatocellular carcinoma in teenagers which are associated with chronic hepatitis of HCV infection. Unfortunately the extent of information about the evolution and treatment is reduced when compared against publications in adults (11).
HCV infection in children differs from infection in adult through transmission paths, spontaneous viral clearance rate (12, 13) , and fibrosis progression duration of chronic infection.
There are reports of deaths of children due to liver failure in the past nine years because of acquisition of infection and hepatocellular carcinoma cases are reported in 25 to 27 years after infection (14) . It is estimated that the rate of children with chronic hepatitis C will develop cirrhosis is less than 2% (15, 16) , however there are reports of children requiring liver transplantation (17) . The scope of this review is to present a general overview of the current treatments for HCV infection in children.
Virology
Hepatitis C virus (HCV) is an enveloped virus from 50 to 80 nm in diameter formed by a positive sense single stranded RNA of which seven are known genotypes and subtypes 100 (18) which belongs to the family Flaviviridae and genus Hepacivirus (19). The viral RNA functions as mRNA and its translation produces a polyprotein precursor of 3010 amino acids and from this functional, structural and nonstructural proteins by cellular and viral proteases will be generated.
Untranslated 5 'and 3' ends contain important regions for viral replication, region nearby 5' end contains information coding for the structural proteins in the regions C, E1, E2 and NS1. The remainder of the genome codes for the nonstructural proteins is encoded by the regions NS2, NS3, NS4 and NS5 (20). The virus must interact with hepatocyte membrane receptors, then endocytosed and released into cytoplasm, there, the RNA is translated directly and peptidases present in the endoplasmic reticulum of the host cell cleave the 5'-end, causing proteins C, E1, E2 and NS1 nonstructural proteins to be released, which are cleaved by the action of viral proteases (21, 22), this cycle allows a wide range of targets. The virus replicates predominantly in the liver, but has tropism for other cells such as T and B lymphocytes, their half-life in blood is 2.7 h, a daily high production of viral particles (23, 24) and the error rate during viral replication is 10 -3 to 10 -5 added to the absence of the error correction by the NS5B polymerase in the same patient allows to identify different quasi species (25), in addition a high rate of polymerase error, a short replicative cycle, the small size genome are factors contributing to the generation of these quasi species, which differ in their biological properties: virulence, cell tropism and ability to evade the immune system (26). The virus can be inactivated at 60° C for 30 minutes or at 100° C for two minutes (27) .
Epidemiology
In 2014, the World Health Organization (WHO) published the "Guidelines for the screening, care and treatment of persons with hepatitis C infection" where the number of infected persons in different regions of the world was described (Table 1 ) (28).
Worldwide studies of incidence and prevalence in children are limited and the clinical manifestations are rare and the diagnosis is usually performed during the realization of screening tests in those have identified risk factors or to diagnose HCV infection in a close relative. The incidence and prevalence are relatively low ranging from 0-0.4 to 14.5% (29) . In the United
States the seroprevalence is 0.2% for those under 12 years of age, and 0.4 for those between 12-19 years old.
Routes of transmission
Globally it is considered that the most common forms of transmission in order of frequency are:
intravenous drug use, blood transfusion, multiple sexual partners, tattoos, piercings and finally the perinatal. Although in some developing countries such as Mexico the most common cause of acquisition of C virus remains transfusion of blood and blood products (30, 31) .
The main route of transmission in children is vertical transmission (32) .there is no evidence of decreased transmission of infection by avoiding breast feeding (33), transmission rates reported for breast fed are 3.7% against 3.9% of formula-fed (34) , is associated with the existence of free fatty acids produced by lipases destroy the lipid envelope of virus (35, 36). It is considered that the risk is greater in the presence of cracks and bleeding from the nipple of the mother. The infection rate among children of mothers with HCV infection is 2 to 18% (37) and is associated with viral load, HIV co-infection, premature rupture of membranes, exposure to 
Clinical manifestations
The diagnosis of chronic hepatitis C in children is usually performed in screening programs, in subjects at risk for having a history of parenteral exposure, or after the discovery of an affected family. The clinical manifestations are rare, were more frequently reported in adolescents as fatigue, anorexia, weight loss, nausea, abdominal discomfort, hepatomegaly (48-50). The histopathological findings in children with chronic hepatitis C are significant liver fibrosis with percentages of 10% (51), which is more intense with increasing age, the degree of hepatic inflammation is related with the duration of less intense infection than in adult patients, has been reported cirrhosis at a rate of 4% (52). The diagnosis of chronic HCV infection should be based on the demonstration of HCV RNA positive at least 3 years after the exposure of risk.
Diagnosis
The importance of establishing the diagnosis is that the clinical manifestations are subtle, but the liver damage is cumulative and increases with time period. Concerning with laboratory studies, it is recommended to test for HCV using RNA PCR at 2 and 6 months of age, and serology for the antibodies against hepatitis C virus to 18 months old.
Natural history of the disease
Symptomatic chronic infection in children is not frequent, as the infection was discovered during routine laboratory tests or during the deliberate search of children of mothers with chronic hepatitis C. Of the patients exposed and infected with the 10% clearance of virus at 12 months after exposure and between 20 to 30% at 24 months, after this period it is less probable for spontaneous clearance (3.5%).
In relation to liver function tests, 90 % of children have elevated transaminases subsequently tend to normalize although the infection persists. Unlike adult evolution is moderate, severe liver damage and cirrhosis only occur in 2% of chronic patients infected with HCV (53), which is attributed to the lack of exposure to alcohol, drugs and concomitant infections that may influence prognosis. There is evidence that the infection progresses to chronicity in 50-60% of children exposed (54, 55).
Histopathology
Due to the nature of the HCV, a RNA virus with a life cycle confined to the cytoplasm (56) 
Treatment
The goal of treatment is to achieve sustained viral clearance in early stages that may alter the natural history of the disease, normalization of liver function tests, reversal of histological lesions and symptoms when present (58) . Both drugs are given in combination therapy in children over 3 years of age (67), with detectable HCV RNA levels greater than 50 IU/mL with liver biopsy with fibrosis, moderate inflammation and necrosis. Similar side effects are reported to adults, including leukopenia, anemia, weight loss (determined by anorexia, nausea, and abdominal pain), changes in behavior, depression, suicidal ideation, thyroid disorders, and transient slowing of the growth rate (68).
Adverse effects determine that about 10-14% of adult patients discontinue their treatment and 4% of pediatric patients (69) . In children treated with pegylated interferon α2a + ribavirin in the PEDS-C trial was evident that the changes in body weight, height, BMI and body composition, some of the effects were reversible except the index weight for age that was not recovered in two years tracking the following initial period, although extended to six years monitoring has shown the recovery rate and the absence of effects on height was long term, (70, 71) .
Prognostic factors for successful response to treatment are identified with infections of genotypes 2 and 3, less than 12 years of age and viral load of less than two million copies, sustained virologic response (SVR) rate is about 50% for children infected with Genotype 1 and 4 (72, 73) , and increased to 90% in those with genotypes 2 and 3 (74) . Recently, it has been approved that the other drugs with direct antiviral activity (DAAs), the protease inhibitors NS3/4, Boceprevir and Telaprevir were introduced into clinical practice in 2011, when they were added to the conventional double therapy, increased the rate of SVR from 25-30% (75), the addition of Sofosbuvir increases the response rate to 90%. The results have been encouraging in adults, but for children no new drugs have been approved yet.
These new drugs block viral proteins in a selective and directed way. Because of the combinations of these drugs, among which may be included or not interferon-α, recent clinical trials obtain a sustained viral response rate above 90% in most patients (76) . (Table 2) . 
